Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rommer

Showing results (41-50 of 255) with videos related to

Pageof 26
Sort By:
Audiology & Neuro-Otology|May 1, 2015
Neuromagnetic cortical activation during initiation of optokinetic nystagmus: an MEG pilot studyPaulus S Rommer, Roland Beisteiner, Kirsten Elwischger, et al.
Current Pharmaceutical Design|July 5, 2021
Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple SclerosisAnja Steinmaurer, Isabella Wimmer, Thomas Berger, et al.
The New England Journal of Medicine|April 14, 1983
Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenonR J Rodeheffer, J A Rommer, F Wigley, et al.
Frontiers in Immunology|March 3, 2020
Editorial: Multiple Sclerosis - From Bench to Bedside: Currents Insights Into Pathophysiological Concepts and Their Potential Impact on PatientsPaulus S Rommer, Martin S Weber, Zsolt Illes, et al.
Biomedicines|November 11, 2022
Immunosenescence in Neurological Diseases-Is There Enough Evidence?Paulus S Rommer, Gabriel Bsteh, Tobias Zrzavy, et al.
Journal of Neurology|May 18, 2021
Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot studyTobias Zrzavy, Anna Pfitzner, Peter Flachenecker, et al.
Clinical and Translational Medicine|February 22, 2024
Ineffective control of Epstein-Barr virus infection is seen in MS: What is next?Paulus Rommer, Elisabeth Puchhammer-Stöckl, Hans Lassmann, et al.
CNS Drugs|June 25, 2011
Rituximab for secondary progressive multiple sclerosis: a case seriesPaulus S Rommer, Robert Patejdl, Alexander Winkelmann, et al.
Expert Review of Clinical Immunology|January 11, 2018
Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledgeUwe Klaus Zettl, Michael Hecker, Orhan Aktas, et al.
Journal of Neurology|March 21, 2009
Monoclonal antibodies in the therapy of multiple sclerosis: an overviewP S Rommer, O Stüve, R Goertsches, et al.
Pageof 26

Showing results (41-50 of 255) with videos related to

Sort By:
Pageof 26
Audiology & Neuro-Otology|May 1, 2015
Neuromagnetic cortical activation during initiation of optokinetic nystagmus: an MEG pilot studyPaulus S Rommer, Roland Beisteiner, Kirsten Elwischger, et al.
Current Pharmaceutical Design|July 5, 2021
Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple SclerosisAnja Steinmaurer, Isabella Wimmer, Thomas Berger, et al.
The New England Journal of Medicine|April 14, 1983
Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenonR J Rodeheffer, J A Rommer, F Wigley, et al.
Frontiers in Immunology|March 3, 2020
Editorial: Multiple Sclerosis - From Bench to Bedside: Currents Insights Into Pathophysiological Concepts and Their Potential Impact on PatientsPaulus S Rommer, Martin S Weber, Zsolt Illes, et al.
Biomedicines|November 11, 2022
Immunosenescence in Neurological Diseases-Is There Enough Evidence?Paulus S Rommer, Gabriel Bsteh, Tobias Zrzavy, et al.
Journal of Neurology|May 18, 2021
Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot studyTobias Zrzavy, Anna Pfitzner, Peter Flachenecker, et al.
Clinical and Translational Medicine|February 22, 2024
Ineffective control of Epstein-Barr virus infection is seen in MS: What is next?Paulus Rommer, Elisabeth Puchhammer-Stöckl, Hans Lassmann, et al.
CNS Drugs|June 25, 2011
Rituximab for secondary progressive multiple sclerosis: a case seriesPaulus S Rommer, Robert Patejdl, Alexander Winkelmann, et al.
Expert Review of Clinical Immunology|January 11, 2018
Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledgeUwe Klaus Zettl, Michael Hecker, Orhan Aktas, et al.
Journal of Neurology|March 21, 2009
Monoclonal antibodies in the therapy of multiple sclerosis: an overviewP S Rommer, O Stüve, R Goertsches, et al.
Pageof 26